Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 31;398(10298):385-387.
doi: 10.1016/S0140-6736(21)01642-1. Epub 2021 Jul 17.

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri  1 , Annalan M D Navaratnam  1 , Vincent Nguyen  1 , Thomas Byrne  1 , Cyril Geismar  1 , Ellen Fragaszy  1 , Sarah Beale  1 , Wing Lam Erica Fong  1 , Parth Patel  1 , Jana Kovar  1 , Andrew C Hayward  1 , Robert W Aldridge  2 ; Virus Watch Collaborative
Affiliations

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. All other authors declare no competing interests. The research costs for the study have been supported by the Medical Research Council Grant awarded to University College London. The study also received US$15 000 of Facebook advertising credit to support a pilot social media recruitment campaign on Aug 18, 2020. Virus Watch received funding via the UK Government Department of Health and Social Care's Vaccine Evaluation Programme to provide monthly Thriva antibody tests to adult participants. This work was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RWA. Author contributions and members of the Virus Watch Collaborative are listed in the appendix.

Figures

Figure
Figure
Levels of antibody against the spike glycoprotein of SARS-CoV-2 (S-antibody) at defined timepoints after second dose of vaccination (with extended dose intervals) in individuals with no previous infection, stratified by vaccine type p values derived from non-parametric tests for trend for each vaccine subgroup are given in parenthesis in the key.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;13:373. - PMC - PubMed
    1. Hayward A, Fragaszy E, Kovar J, et al. Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study. BMJ Open. 2021;11 - PMC - PubMed
    1. The National SARS-CoV-2 Serology Assay Evaluation Group Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20:1390–1400. - PMC - PubMed